
Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as injectable medicines from Amgen and Regeneron.

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as injectable medicines from Amgen and Regeneron.